221 related articles for article (PubMed ID: 26630226)
21. [MED12 gene mutations in women with uterine myoma].
Osinovskaya NS; Ivashchenko TE; Dolinskii AK; Sultanov IY; Ghimbovchi S; Hoffman E; Bezhenar VF; Baranov VS
Genetika; 2013 Dec; 49(12):1426-31. PubMed ID: 25438604
[TBL] [Abstract][Full Text] [Related]
22. Exomic landscape of MED12 mutation-negative and -positive uterine leiomyomas.
Mäkinen N; Vahteristo P; Bützow R; Sjöberg J; Aaltonen LA
Int J Cancer; 2014 Feb; 134(4):1008-12. PubMed ID: 23913526
[TBL] [Abstract][Full Text] [Related]
23. Selective genetic analysis of myoma pseudocapsule and potential biological impact on uterine fibroid medical therapy.
Di Tommaso S; Massari S; Malvasi A; Vergara D; Maffia M; Greco M; Tinelli A
Expert Opin Ther Targets; 2015 Jan; 19(1):7-12. PubMed ID: 25363374
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of MED12 mutations in uterine and extrauterine smooth muscle tumours.
Matsubara A; Sekine S; Yoshida M; Yoshida A; Taniguchi H; Kushima R; Tsuda H; Kanai Y
Histopathology; 2013 Mar; 62(4):657-61. PubMed ID: 23347103
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and clinical significance of mediator complex subunit 12 mutations in 362 Han Chinese samples with uterine leiomyoma.
Wu J; Zou Y; Luo Y; Guo JB; Liu FY; Zhou JY; Zhang ZY; Wan L; Huang OP
Oncol Lett; 2017 Jul; 14(1):47-54. PubMed ID: 28693134
[TBL] [Abstract][Full Text] [Related]
26. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists.
Nagai K; Asano R; Sekiguchi F; Asai-Sato M; Miyagi Y; Miyagi E
Am J Obstet Gynecol; 2023 Feb; 228(2):207.e1-207.e9. PubMed ID: 36150519
[TBL] [Abstract][Full Text] [Related]
27. Cell cultures in uterine leiomyomas: rapid disappearance of cells carrying MED12 mutations.
Nadine Markowski D; Tadayyon M; Bartnitzke S; Belge G; Maria Helmke B; Bullerdiek J
Genes Chromosomes Cancer; 2014 Apr; 53(4):317-23. PubMed ID: 24446130
[TBL] [Abstract][Full Text] [Related]
28. Uterine Leiomyomas with an Apparently Normal Karyotype Comprise Minor Heteroploid Subpopulations Differently Represented in vivo and in vitro.
Koltsova AS; Efimova OA; Pendina AA; Chiryaeva OG; Osinovskaya NS; Shved NY; Yarmolinskaya MI; Polenov NI; Kunitsa VV; Sagurova YM; Tral TG; Tolibova GK; Baranov VS
Cytogenet Genome Res; 2021; 161(1-2):43-51. PubMed ID: 33550288
[TBL] [Abstract][Full Text] [Related]
29. Analysis of
Lee M; Cheon K; Chae B; Hwang H; Kim HK; Chung YJ; Song JY; Cho HH; Kim JH; Kim MR
Int J Med Sci; 2018; 15(2):124-128. PubMed ID: 29333096
[TBL] [Abstract][Full Text] [Related]
30. Mediator Kinase Disruption in MED12-Mutant Uterine Fibroids From Hispanic Women of South Texas.
Park MJ; Shen H; Kim NH; Gao F; Failor C; Knudtson JF; McLaughlin J; Halder SK; Heikkinen TA; Vahteristo P; Al-Hendy A; Schenken RS; Boyer TG
J Clin Endocrinol Metab; 2018 Nov; 103(11):4283-4292. PubMed ID: 30099503
[TBL] [Abstract][Full Text] [Related]
31. MED12 and uterine smooth muscle oncogenesis: State of the art and perspectives.
Croce S; Chibon F
Eur J Cancer; 2015 Aug; 51(12):1603-10. PubMed ID: 26037152
[TBL] [Abstract][Full Text] [Related]
32. Mediator complex subunit 12 exon 2 mutation analysis in different subtypes of smooth muscle tumors confirms genetic heterogeneity.
de Graaff MA; Cleton-Jansen AM; Szuhai K; Bovée JV
Hum Pathol; 2013 Aug; 44(8):1597-604. PubMed ID: 23517922
[TBL] [Abstract][Full Text] [Related]
33. Detection of MED12 mutations in mesenchymal components of uterine adenomyomas.
Kito M; Maeda D; Kudo-Asabe Y; Tamura D; Makino K; Sageshima M; Nanjo H; Terada Y; Goto A
Hum Pathol; 2021 Mar; 109():31-36. PubMed ID: 33259844
[TBL] [Abstract][Full Text] [Related]
34. MED12 exon 2 mutations are common in uterine leiomyomas from South African patients.
Mäkinen N; Heinonen HR; Moore S; Tomlinson IP; van der Spuy ZM; Aaltonen LA
Oncotarget; 2011 Dec; 2(12):966-9. PubMed ID: 22182697
[TBL] [Abstract][Full Text] [Related]
35. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma.
Bertsch E; Qiang W; Zhang Q; Espona-Fiedler M; Druschitz S; Liu Y; Mittal K; Kong B; Kurita T; Wei JJ
Mod Pathol; 2014 Aug; 27(8):1144-53. PubMed ID: 24390224
[TBL] [Abstract][Full Text] [Related]
36. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors.
Mäkinen N; Kämpjärvi K; Frizzell N; Bützow R; Vahteristo P
Mol Cancer; 2017 Jun; 16(1):101. PubMed ID: 28592321
[TBL] [Abstract][Full Text] [Related]
37. Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.
Kämpjärvi K; Mäkinen N; Kilpivaara O; Arola J; Heinonen HR; Böhm J; Abdel-Wahab O; Lehtonen HJ; Pelttari LM; Mehine M; Schrewe H; Nevanlinna H; Levine RL; Hokland P; Böhling T; Mecklin JP; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2012 Nov; 107(10):1761-5. PubMed ID: 23132392
[TBL] [Abstract][Full Text] [Related]
38. MED12 alterations in both human benign and malignant uterine soft tissue tumors.
Pérot G; Croce S; Ribeiro A; Lagarde P; Velasco V; Neuville A; Coindre JM; Stoeckle E; Floquet A; MacGrogan G; Chibon F
PLoS One; 2012; 7(6):e40015. PubMed ID: 22768200
[TBL] [Abstract][Full Text] [Related]
39. MED12 mutations in leiomyosarcoma and extrauterine leiomyoma.
Ravegnini G; Mariño-Enriquez A; Slater J; Eilers G; Wang Y; Zhu M; Nucci MR; George S; Angelini S; Raut CP; Fletcher JA
Mod Pathol; 2013 May; 26(5):743-9. PubMed ID: 23222489
[TBL] [Abstract][Full Text] [Related]
40. MED12 mutations and FH inactivation are mutually exclusive in uterine leiomyomas.
Kämpjärvi K; Mäkinen N; Mehine M; Välipakka S; Uimari O; Pitkänen E; Heinonen HR; Heikkinen T; Tolvanen J; Ahtikoski A; Frizzell N; Sarvilinna N; Sjöberg J; Bützow R; Aaltonen LA; Vahteristo P
Br J Cancer; 2016 Jun; 114(12):1405-11. PubMed ID: 27187686
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
